Charles Zhao

Charles Zhao, M.D., MBA, brings more than 20 years of drug development experience in the oncology therapeutic area. Before Elpis, Charles served as CMO at ABM Therapeutics and Sr. Medical Director at Mirati Therapeutics. Previously, he was Medical Director at EMD Serono working on the cMET inhibitor global program in hepatocellular carcinoma indication; MEK inhibitor early phase development program in multiple indications including pancreatic cancer, ovarian cancer, melanoma, NSCLC, CRC, TNBC, and CML; and MetAP2 inhibitor early phase development program. He was Associate Medical Director at Boehringer Ingelheim working on PLK1 inhibitors in urothelial carcinoma and AML indication. His career highlights also include his work at Novartis working on HDAC inhibitor in CTCL and PKC inhibitor in AML indication, and Eli Lilly in early phase clinical development.